{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 1611, "factors": [{"GSE5967GSM138612": {}}, {"GSE5967GSM138607": {}}, {"GSE5967GSM138605": {}}, {"GSE5967GSM138601": {}}, {"GSE5967GSM138598": {}}, {"GSE5967GSM138600": {}}, {"GSE5967GSM138611": {}}, {"GSE5967GSM138604": {}}, {"GSE5967GSM138608": {}}, {"GSE5967GSM138609": {}}, {"GSE5967GSM138603": {}}, {"GSE5967GSM138617": {}}, {"GSE5967GSM138616": {}}, {"GSE5967GSM138599": {}}, {"GSE5967GSM138602": {}}, {"GSE5967GSM138615": {}}, {"GSE5967GSM138597": {}}, {"GSE5967GSM138610": {}}, {"GSE5967GSM138614": {}}, {"GSE5967GSM138613": {}}, {"GSE5967GSM138606": {}}], "ownerprofile_id": "arrayexpress_sid", "platform": 3, "summary_wrapped": "BACKGROUND: Assessment of gene expression in peripheral blood may provide a noninvasive screening test for allograft rejection. We...", "pubmed_id": 15583081, "geo_gse_id": "E-GEOD-5967", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 0, "sample_count": 21, "tags": ["heart", "intermediate", "lung", "peripheral"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-of-human-peripheral-bloo-6", "geo_id_plat": "E-GEOD-5967_A-AFFY-33", "name": "Transcription profiling of human peripheral blood to detect cardiac allograft rejection and response to immunosuppressive therapy", "created": "Jun.19, 2014", "summary": "BACKGROUND: Assessment of gene expression in peripheral blood may provide a noninvasive screening test for allograft rejection. We hypothesized that changes in peripheral blood expression profiles would correlate with biopsy-proven rejection and would resolve after treatment of rejection episodes. METHODS AND RESULTS: We performed a case-control study nested within a cohort of 189 cardiac transplant patients who had blood samples obtained during endomyocardial biopsy (EMB). Using Affymetrix HU133A microarrays, we analyzed whole-blood expression profiles from 3 groups: (1) control samples with negative EMB (n=7); (2) samples obtained during rejection (at least International Society for Heart and Lung Transplantation grade 3A; n=7); and (3) samples obtained after rejection, after treatment and normalization of the EMB (n=7). We identified 91 transcripts differentially expressed in rejection compared with control (false discovery rate <0.10). In postrejection samples, 98% of transcripts returned toward control levels, displaying an intermediate expression profile for patients with treated rejection (P<0.0001). Cluster analysis of the 40 transcripts with >25% change in expression levels during rejection demonstrated good discrimination between control and rejection samples and verified the intermediate expression profile of postrejection samples. Quantitative real-time polymerase chain reaction confirmed significant differential expression for the predictive markers CFLAR and SOD2 (UniGene ID No. 355724 and No. 384944). CONCLUSIONS: These data demonstrate that peripheral blood expression profiles correlate with biopsy-proven allograft rejection. Intermediate expression profiles of treated rejection suggest persistent immune activation despite normalization of the EMB. If validated in larger studies, expression profiling may prove to be a more sensitive screening test for allograft rejection than EMB. Experiment Overall Design: Case- control study with three groups.  Patients with rejection (r1-r7), follow-up samples after treatment of rejection (post1-7), and controls with no rejection (con1-7)", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-5967", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-5967/samples/"}